Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when AIDX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alerts20/20 Biolabs reports full-year 2025 financial results via press release
Filed April 1, 2026 · Period ending March 31, 2026 · ~1 min read
Key Changes
-
high
Company issued press release disclosing financial results for year ended December 31, 2025. Actual revenue, earnings, and performance metrics are in the attached exhibit, not the 8-K body itself.
Item 2.02 verify on EDGAR → -
medium
Filing references March 31, 2026 press release but provides no financial details in the main document. Investors must review Exhibit 99.1 for complete results.
8-K: Earnings view on EDGAR →
Summary
20/20 Biolabs announced its full-year 2025 financial results on March 31, 2026, through a press release filed as an exhibit to this 8-K. The filing itself is a standard earnings disclosure wrapper—the actual financial performance data, including revenue, net income, and key operating metrics, are contained in the attached press release rather than in the body of the 8-K. Retail investors should review Exhibit 99.1 to assess how the company performed in 2025 and whether results met, exceeded, or fell short of expectations.
Pay particular attention to year-over-year growth trends, cash position, and any forward guidance provided in the release.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On March 31, 2026, 20/20 Biolabs, Inc. (the “Company”) issued a press release regarding its financial results for the year ended December 31, 2025.
The company announced its full-year 2025 financial results via press release. The 8-K itself does not contain the actual financial figures, only references that a press release was issued as Exhibit 99.1. Investors would need to review the attached exhibit to see revenue, earnings, and other performance metrics.
Event · Item 9.01 — Financial Statements and Exhibits
20/20 Biolabs filed an 8-K referencing a press release issued March 31, 2026; no material event details disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Press Release issued on March 31, 2026
The 8-K references a press release issued March 31, 2026, but does not disclose the content or subject matter of that release within the filing body. Without the exhibit text, the materiality and nature of the disclosed event cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify